Systemic administration of naked plasmid encoding hepatocyte growth factor ameliorates chronic renal fibrosis in mice

被引:79
作者
Yang, J [1 ]
Dai, C [1 ]
Liu, Y [1 ]
机构
[1] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA
关键词
HGF; c-met; gene therapy; chronic renal disease; renal fibrosis; UUO;
D O I
10.1038/sj.gt.3301545
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The progression of chronic renal diseases Is considered as an irreversible process that eventually leads to end-stage renal failure characterized by extensive tissue fibrosis. At present, chronic renal fibrosis is incurable and the incidence of affected patients is on the rise worldwide. In this study, we demonstrate that delivery of hepatocyte growth factor (HGF) gene via systemic administration of naked plasmid vector markedly ameliorated renal fibrosis in an animal model of chronic renal disease induced by unilateral ureteral obstruction. A high level of exogenous HGF protein was detected in the obstructed kidneys following intravenous injection of naked plasmid encoding human HGF Delivery of human HGF gene induced a sustained activation of extracellular signal-regulated kinases-1 and -2 in the obstructed kidneys. Exogenous HGF expression dramatically inhibited a-smooth muscle actin expression, attenuated renal interstitial accumulation and deposition of collagen I and fibronectin. In addition, exogenous HGF suppressed renal expression of pro-fibrogenic cytokine TGF-beta1 and its type I receptor in vivo. These results suggest that systemic administration of naked plasmid vector introduces a high level of exogenous HGF to the diseased kidneys, and that HGF gene transfer may provide a novel therapeutic strategy for amelioration of chronic renal fibrosis in vivo.
引用
收藏
页码:1470 / 1479
页数:10
相关论文
共 45 条
[1]   The five amino acid-deleted isoform of hepatocyte growth factor promotes carcinogenesis in transgenic mice [J].
Bell, A ;
Chen, QY ;
DeFrances, MC ;
Michalopoulos, GK ;
Zarnegar, R .
ONCOGENE, 1999, 18 (04) :887-895
[2]   Interactions of transforming growth factor-β and angiotensin II in renal fibrosis [J].
Border, WA ;
Noble, NA .
HYPERTENSION, 1998, 31 (01) :181-188
[3]   Mammalian MAP kinase signalling cascades [J].
Chang, LF ;
Karin, M .
NATURE, 2001, 410 (6824) :37-40
[4]   Renal tubulointerstitial injury from ureteral obstruction in the neonatal rat is attenuated by IGF-1 [J].
Chevalier, RL ;
Goyal, S ;
Kim, A ;
Chang, AY ;
Landau, D ;
LeRoith, D .
KIDNEY INTERNATIONAL, 2000, 57 (03) :882-890
[5]  
Eddy AA, 1996, J AM SOC NEPHROL, V7, P2495
[6]   Hepatocyte growth factor, but not insulin-like growth factor I, protects podocytes against cyclosporin A-induced apoptosis [J].
Fornoni, A ;
Li, H ;
Foschi, A ;
Striker, GE ;
Striker, LJ .
AMERICAN JOURNAL OF PATHOLOGY, 2001, 158 (01) :275-280
[7]   Hepatocyte growth factor overexpression in the islet of transgenic mice increases beta cell proliferation, enhances islet mass, and induces mild hypoglycemia [J].
Garcia-Ocaña, A ;
Takane, KK ;
Syed, MA ;
Philbrick, WM ;
Vasavada, RC ;
Stewart, AF .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (02) :1226-1232
[8]  
HAMMERMAN MR, 2000, AM J PHYSIOL-RENAL, V279, pF3
[9]   Intravenous injection of naked DNA encoding secreted flt3 ligand dramatically increases the number of dendritic cells and natural killer cells in vivo [J].
He, YK ;
Pimenov, AA ;
Nayak, JV ;
Plowey, J ;
Falo, LD ;
Huang, L .
HUMAN GENE THERAPY, 2000, 11 (04) :547-554
[10]   New paradigm of gene therapy: Skeletal-muscle-targeting gene therapy for kidney disease [J].
Imai, E ;
Isaka, Y .
NEPHRON, 1999, 83 (04) :296-300